Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.

Dufour BD, McBride JL.

Exp Neurol. 2016 Sep;283(Pt A):308-17. doi: 10.1016/j.expneurol.2016.06.028.

PMID:
27381424
2.

Stereotaxic Surgical Targeting of the Nonhuman Primate Caudate and Putamen: Gene Therapy for Huntington's Disease.

McBride JL, Clark RL.

Methods Mol Biol. 2016;1382:409-28. doi: 10.1007/978-1-4939-3271-9_29.

PMID:
26611603
3.

Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

Keiser MS, Kordasiewicz HB, McBride JL.

Hum Mol Genet. 2016 Apr 15;25(R1):R53-64. doi: 10.1093/hmg/ddv442. Review.

PMID:
26503961
4.

Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery.

Dufour BD, McBride JL.

Methods Mol Biol. 2016;1364:261-75. doi: 10.1007/978-1-4939-3112-5_21.

PMID:
26472457
5.

Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain.

Monteys AM, Spengler RM, Dufour BD, Wilson MS, Oakley CK, Sowada MJ, McBride JL, Davidson BL.

Nucleic Acids Res. 2014 Dec 1;42(21):13315-27. doi: 10.1093/nar/gku979.

6.

Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL.

Mol Ther. 2014 Apr;22(4):797-810. doi: 10.1038/mt.2013.289.

7.

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.

McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL.

Mol Ther. 2011 Dec;19(12):2152-62. doi: 10.1038/mt.2011.219.

8.

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH.

Hum Mol Genet. 2012 Jan 15;21(2):406-20. doi: 10.1093/hmg/ddr475.

9.

Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.

Hadaczek P, Forsayeth J, Mirek H, Munson K, Bringas J, Pivirotto P, McBride JL, Davidson BL, Bankiewicz KS.

Hum Gene Ther. 2009 Mar;20(3):225-37. doi: 10.1089/hum.2008.151.

10.

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL.

Mol Ther. 2009 Jun;17(6):1053-63. doi: 10.1038/mt.2009.17.

11.

Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.

Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH.

Neurobiol Dis. 2009 Apr;34(1):40-50. doi: 10.1016/j.nbd.2008.12.005.

PMID:
19150499
12.

Restoring Acid-sensing ion channel-1a in the amygdala of knock-out mice rescues fear memory but not unconditioned fear responses.

Coryell MW, Wunsch AM, Haenfler JM, Allen JE, McBride JL, Davidson BL, Wemmie JA.

J Neurosci. 2008 Dec 17;28(51):13738-41. doi: 10.1523/JNEUROSCI.3907-08.2008.

13.

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73. doi: 10.1073/pnas.0801775105.

14.

Animal models of Huntington's disease.

Ramaswamy S, McBride JL, Kordower JH.

ILAR J. 2007;48(4):356-73. Review.

PMID:
17712222
15.

Transvascular delivery of small interfering RNA to the central nervous system.

Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N.

Nature. 2007 Jul 5;448(7149):39-43.

PMID:
17572664
16.

Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.

Ramaswamy S, McBride JL, Herzog CD, Brandon E, Gasmi M, Bartus RT, Kordower JH.

Neurobiol Dis. 2007 May;26(2):375-84.

PMID:
17336076
17.

Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9345-50.

18.

Human neural stem cell transplants improve motor function in a rat model of Huntington's disease.

McBride JL, Behrstock SP, Chen EY, Jakel RJ, Siegel I, Svendsen CN, Kordower JH.

J Comp Neurol. 2004 Jul 19;475(2):211-9.

PMID:
15211462
19.

Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.

McBride JL, During MJ, Wuu J, Chen EY, Leurgans SE, Kordower JH.

Exp Neurol. 2003 Jun;181(2):213-23.

PMID:
12781994
20.

Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF.

McBride JL, Kordower JH.

Prog Brain Res. 2002;138:421-32. Review. No abstract available.

PMID:
12432782
Items per page

Supplemental Content

Loading ...
Support Center